Wikipedia -WSS

Wikipedia

author：hotspot 2025-09-30 00:35:39 - browse：19

Courtesy Guardant Health

An independent panel of advisers to the Food and Drug Administration recommended the agency approve Guardant Health’s blood-based colon cancer detection test. If the agency follows the recommendation, it will clear an early hurdle for the test’s broader adoption.

The expert panel spent hours listening to presentations from Guardant, the FDA, and members of the public before voting on the screening test, called Shield. The panel’s nine voting members then voted on whether the test was safe, effective, and whether its benefits outweigh its risks, with eight, six, and seven panelists endorsing those views, respectively.

FDA approval is a requirement for winning coverage from the Centers for Medicare and Medicaid Services, which could be the difference between Guardant’s test becoming widespread — or irrelevant. In 2021, CMS denied coverage for Epi proColon, a different blood-based colon cancer test approved by the FDA. Soon after, the test’s maker, Epigenomics, announced that it would stop actively marketing the test, and last year the company announced a restructuring that included layoffs.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Methadone treatment changes are coming. Do they go far enough?

WSS

Nurses recount patients attacks

A new nitrogen execution bill also undermines medical licensing

Intermittent fasting comes with a heart risk? Not so fast

Alabama frozen embryo ruling has major implications for IVF clinics

STAT readers on older presidents, polypills, Medicare, and more

Creating egg and sperm cells from stem cells raises ethical issues

hotspot

Wikipedia

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

How one medical school became remarkably diverse

Physicians and social media: If you see something, say something?

In Memoriam: Notable people who died in 2023

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

Continuity nursing helped my family in our darkest PICU moments

New documents shed light on MD Anderson Cancer Institute feud

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

Wildfire smoke exposes gaps in outdoor worker protections

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

leisure time

Argenx readies a blockbuster opportunity with drug for autoimmune disease

A solution to the after

Physicians and social media: If you see something, say something?

Leading voice in opioid treatment defends methadone clinic system

Asbestos, a deadly carcinogen, banned by EPA

Readout Newsletter: Geron, Novo Nordisk, WuXi updates

explore

leisure time

explore

knowledge